New site for Flamma

CDMO Flamma has acquired a third API manufacturing facility in Italy from Teva. The Sicor Bulciago site at Lecco has had multiple regulatory inspections. Terms were not disclosed.

“This allows us to rapidly enhance our CMC offerings to our customers by providing further flexibility between sites,” said CEO Dr Gianpaolo Negrisoli. “Having the ability to produce more generic APIs in Italy is in line with the European pharmaceutical strategy aiming to reshore.”

Lecco is only 30 km from Flamma’s headquarters site at Chignolo d’Isola and many current Flamma employees previously worked there, the company added. Its 600 m3 of capacity brings the company’s total in Italy to over 900. Flamma will shortly add a further 600 at the Flamma Honkai site in China.

In recent years, Flamma has added a site at Malvern, Pennsylvania, for early stage small molecule projects. It will soon complete an expansion at Chignolo d’Isola that will quadruple R&D space and add further analytical resources. It will invest more than €150 million to add capacity and capability across all three continents over the next three years.